Form 4: Lexeo CDO Plans Future Stock Sale for Tax Obligations

Lexeo Therapeutics' Chief Development Officer, Sandi See Tai, reported a planned sale of 386 common stock shares on November 18, 2025, at a weighted average price of $9.27 to cover tax obligations from restricted stock units.

Summary

• Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, Inc. (LXEO), filed a Form 4.
• The filing reports a planned transaction on November 18, 2025, involving the disposition of 386 shares of common stock.
• The sale is intended to cover tax obligations arising from the release of restricted stock units (RSUs).
• The shares were sold at a weighted average price of $9.27 per share, with individual trades ranging from $9.09 to $9.37.
• Following this transaction, Sandi See Tai will beneficially own 65,476 shares of common stock, which includes 48,098 RSUs.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine sale to cover tax obligations on restricted stock units, which is a common and expected event for executives receiving equity compensation. It does not indicate a change in the company's fundamental outlook or the executive's confidence.

Future Outlook

The filing indicates a pre-planned future transaction on November 18, 2025, to address tax obligations related to restricted stock units, suggesting a routine financial management action by an executive.

Industry Context

This is a routine insider transaction common across all industries, where executives sell a portion of their vested equity to cover tax liabilities associated with RSU releases. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, pre-planned tax-related sale by an insider and not indicative of a change in company fundamentals or executive sentiment.

Key Dates

Keywords

Lexeo Therapeutics, LXEO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Obligations, Chief Development Officer